Protagonist Therapeutics (PTGX) earnings, Sep 30, 2026: EPS +595%, stock −1.2%
In brief
Protagonist Therapeutics reported on Sep 30, 2026. Earnings per share changed +595% year over year, 22.5% above the estimate; revenue +5,724%. The stock opened with a −1.2% gap and closed the day −1.2% (Oct 1, 2026). The stock is now 15.9% below its 52-week high, +73.7% over 12 months. Next report: Nov 6, 2026.
EPS vs estimate+22.5%
EPS, YoY+595%
Revenue, YoY+5,724%
Gap · day−1.2% · −1.2%
EPS growth by quarter, YoY
Price reaction to earnings
| Report | Gap | Day |
|---|---|---|
| Aug 5, 2026 | +5.6% | +6.5% |
| Sep 30, 2026 | −1.2% | −1.2% |
Next-quarter estimates, ratings and the PTGX chart are in the terminal.
Open the terminalFAQ
When is Protagonist Therapeutics's next earnings report?
Nov 6, 2026. The date comes from daily data and is corrected if the company moves it.
How did Protagonist Therapeutics stock react to the report?
Opening gap −1.2%, day's result −1.2%.
Did Protagonist Therapeutics's earnings grow?
Earnings per share rose 595% year over year.
What is an earnings gap?
The jump between the close before and the open after the report. A big gap up often means large buyers are revaluing the company.